|
May 9
|
DBV Technologies to Participate in Upcoming Investor Conferences
|
|
May 7
|
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
|
|
Apr 25
|
Combined General Meeting of May 16, 2024
|
|
Apr 4
|
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
|
|
Mar 8
|
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript
|
|
Mar 8
|
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
|
|
Mar 7
|
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
|
|
Mar 4
|
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
|
|
Jan 16
|
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
|
|
Dec 4
|
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
|
|
Nov 9
|
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
|
|
Nov 6
|
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
|
|
Nov 2
|
DBV Technologies to Present New Data at ACAAI 2023
|
|
Nov 1
|
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript
|
|
Oct 31
|
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results
|
|
Sep 5
|
DBV Technologies to Participate in Upcoming Investor Conference
|